Annovis Bio, Inc. · NYSE (us_market)
Healthcare · Biotechnology · United States
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-28$5.10 RISE2026-04-10$1.59 PEAK2026-05-06$2.40 159d | -68.8% 133d | Missed | Missed | — | — | +50.9% 26d | Missed |
DROP2025-11-28$5.10 RISE2026-02-13$2.37 PEAK2026-02-25$2.88 89d | -53.5% 77d | Missed | Missed | — | — | +21.5% 12d | Missed |
DROP2025-11-28$5.10 RISE2026-02-11$2.37 PEAK2026-02-25$2.88 89d | -53.5% 75d | Missed | Missed | — | — | +21.5% 14d | Missed |
DROP2025-06-04$3.24 RISE2025-10-13$1.66 PEAK2025-11-28$5.10 177d | -48.8% 131d | Missed | Missed | — | — | +207.2% 46d | Missed |
DROP2025-06-04$3.24 RISE2025-06-27$2.05 PEAK2025-07-28$2.93 54d | -36.7% 23d | Missed | Missed | — | — | +42.9% 31d | Missed |
DROP2024-12-06$6.00 RISE2025-04-17$1.22 PEAK2025-06-04$3.24 180d | -79.7% 132d | Missed | Missed | — | — | +165.6% 48d | Missed |
DROP2024-12-03$6.39 RISE2025-04-15$1.22 PEAK2025-06-04$3.24 183d | -80.9% 133d | Missed | Missed | — | — | +165.6% 50d | Missed |
DROP2024-12-02$7.28 RISE2025-04-08$1.22 PEAK2025-06-04$3.24 184d | -83.2% 127d | Missed | Missed | — | — | +165.6% 57d | Missed |
DROP2024-10-25$9.87 RISE2024-12-20$4.37 PEAK2025-01-03$5.39 70d | -55.7% 56d | Missed | Missed | — | — | +23.3% 14d | Missed |
DROP2024-07-08$15.46 RISE2024-10-14$7.51 PEAK2024-10-25$9.87 109d | -51.4% 98d | Missed | Missed | — | — | +31.4% 11d | Missed |
DROP2024-04-26$18.01 RISE2024-08-09$7.69 PEAK2024-10-25$9.87 182d | -57.3% 105d | Missed | Missed | — | — | +28.3% 77d | Missed |
DROP2024-04-26$18.01 RISE2024-07-01$5.27 PEAK2024-07-08$15.46 73d | -70.7% 66d | Missed | Missed | — | — | +193.4% 7d | Missed |
DROP2023-12-28$19.56 RISE2024-05-08$4.82 PEAK2024-07-08$15.46 193d | -75.4% 132d | Missed | Missed | — | — | +220.7% 61d | Missed |
DROP2023-12-27$19.62 RISE2024-02-29$8.47 PEAK2024-04-26$18.01 121d | -56.8% 64d | Missed | Missed | — | — | +112.6% 57d | Missed |
DROP2023-12-27$19.62 RISE2024-01-24$9.09 PEAK2024-04-11$12.20 106d | -53.7% 28d | Missed | Missed | — | — | +34.2% 78d | Missed |
1–15 / 33 1 / 3 | |||||||
No scored news yet for a sentiment trend.
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock, will be exercisable immediately following the issue date and will expire six years after the date of
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expected Q4 results, with adjusted earnings of 11 cents per share and revenue of $185.25 million. GCL, PETZ, WOK, MEHA, HAO, TDIC, FEED, KELYA, and AMC were among the top gainers, while RUBI, AMIX, IPW, ANVS, and WGRX were among the top losers in pre-market trading.
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Drug...
MALVERN, Pa., May 07, 2026 -- Annovis Bio, Inc. , a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as...
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and...
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.
MALVERN, Pa. - Annovis Bio, Inc. , a Phase 3 clinical - stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease...
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolledMALVERN,
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANVS | -4.00% | -28.09% | -44.51% | -18.30% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.97% | -22.37% | -41.07% | -30.99% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 627.7K | $1.40M | 0.00% | Added+13.7% | 2026-03-31 |
| RenTech | quant | 347.6K | $775.15K | 0.00% | New | 2026-03-31 |
| StateStreet | passive | 77.7K | $173.35K | 0.00% | Added+5.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | -0.35 | -0.63 | -80.00% |
| 2026-03-13 | -0.30 | -0.39 | -30.00% |
| 2025-11-12 | -0.37 | -0.37 | — |
| 2025-08-12 | -0.39 | -0.32 | +17.95% |
| 2025-05-13 | -0.29 | -0.32 | -10.34% |
| 2025-03-21 | -0.33 | -0.43 | -30.30% |
| 2024-11-08 | -0.60 | -0.97 | -62.75% |
| 2024-08-14 | -0.67 | -0.44 | +34.00% |
| 2024-05-10 | -0.84 | -0.10 | +88.06% |
| 2024-03-29 | -1.37 | -2.33 | -69.58% |
| 2023-11-08 | -1.09 | -1.63 | -49.54% |
| 2023-08-14 | -1.14 | -1.07 | +6.14% |
| 2023-05-10 | -0.59 | -1.19 | -101.69% |
| 2023-03-31 | -1.05 | -0.38 | +63.92% |
| 2022-11-08 | -1.01 | -0.93 | +8.22% |
| 2022-08-08 | -0.71 | -1.07 | -50.70% |